For the Inventor, By the Inventor

Enter assignee name

Valbonne, France

Centre International De Recherches Dermatologiques Galderma

USPTO Granted Patents = 44

CIPO Patents = 1

Forward Citations = 432

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Jean-Michel Bernardon (21 out of 86 patents)

Bruno Charpentier (7 out of 14 patents)

Braham Shroot (6 out of 98 patents)

4. Michel Demarchez (6 out of 6 patents)

5. Philippe Diaz (5 out of 16 patents)

6. Uwe Reichert (5 out of 12 patents)

7. Andre Jomard (4 out of 12 patents)

8. Philippe Nedoncelle (4 out of 13 patents)

9. Irina Safonova (4 out of 5 patents)

10. Paul Grimaldi (4 out of 4 patents)

11. Etienne Thoreau (2 out of 19 patents)

12. Bruno Bernard (2 out of 29 patents)

13. Laurence Vigne (2 out of 2 patents)

14. Gerard Ailhaud (2 out of 2 patents)

15. Josiane Allec (2 out of 25 patents)

Core Competencies:

Bicyclic Aromatic Compounds

Polyaromatic Heterocyclic Compounds

Bioactive Bicyclic Aromatic Compounds

Retinoic Acid Inhibitors

Preadipocytic Cell Differentiation

Pharmaceutical Compositions

Cosmetic Compositions

Apoptosis Modulation

Adamantyl-Substituted Compounds

Dibenzofuran Derivatives

RXR Receptor Agonists

Polycyclic Aromatic Compounds

44 patents: Sort by Forward Citations

1. 6515021 - Bicyclic aromatic compounds (2003-02-04),

2. 6506796 - Use of a RAR-&ggr;-specific agonist ligand for increasing the rate of apoptosis (2003-01-14),

3. 6258775 - Bi-aromatic compounds, pharmaceutical and cosmetic compositions containing same and uses (2001-07-10),

4. 6248791 - Stimulating the differentiation of preadipocytic cells and therapies based thereon (2001-06-19),

5. 6248749 - Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation (2001-06-19),

6. 6211239 - Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) (2001-04-03),

7. 6194450 - Polyaromatic heterocyclic compounds and pharmaceutical compositions comprised thereof (2001-02-27),

8. 6171603 - Bioaromatic amido compounds and pharmaceutical/cosmetic compositions comprised thereof (2001-01-09),

9. 6162815 - RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic (2000-12-19),

10. 6162445 - Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions (2000-12-19),

11. 6156788 - Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions (2000-12-05),

12. 6156750 - Bioactive bicyclic aromatic compounds and pharmaceutical/cosmetic (2000-12-05),

13. 6147255 - Bicyclic-aromatic compounds (2000-11-14),

14. 6057341 - Bi-aromatic dibenzofuran derivatives and their use in human and (2000-05-02),

15. 6046220 - Propynyl or dienyl biaromatic compounds (2000-04-04),

Centre International de Recherches Dermatologiques Galderma (Galderma) is a global dermatology company that specializes in the research, development, and commercialization of innovative dermatological solutions. With a strong focus on medical dermatology, Galderma offers a wide range of products and treatment options for various skin conditions and diseases. Their mission is to enhance the quality of life of individuals living with dermatological conditions by providing effective and safe solutions that are backed by scientific research and clinical data. Galderma is dedicated to continuous improvement and pioneering new advancements in the field of dermatology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

44 Patents

#2 in Valbonne

#508 in France

#15,296 in the World

Valbonne, France

Centre International De Recherches Dermatologiques Galderma

Forward Citations = 432

37 inventors:

Jean-Michel Bernardon (21 out of 86 patents)

Bruno Charpentier (7 out of 14 patents)

Braham Shroot (6 out of 98 patents)

4. Michel Demarchez (6 out of 6 patents)

5. Philippe Diaz (5 out of 16 patents)

Please report any incorrect information to support@idiyas.com

Loading…